Millions at Risk: Komen Speaks Out Against House Reconciliation Bill
Breast cancer patients could lose coverage, face delays in critical care
DALLAS, May 22, 2025--(BUSINESS WIRE)--Susan G. Komen®, the world's leading nonprofit breast cancer organization, is deeply troubled by passage of legislation by the House of Representatives which drastically cuts funding for federal health insurance programs and implements damaging reforms. The Congressional Budget Office estimates these changes, combined with the failure to renew health care tax credits, could cause nearly 14 million people to lose their insurance coverage, increasing the U.S. uninsured rate by 30%. Put simply, if enacted into law, this legislation will inflict serious harm on the breast cancer community.
Medicaid and the Affordable Care Act (ACA) Marketplaces often serve as a lifeline for many people in the breast cancer community, from those seeking screening to those in treatment and beyond. In the U.S., more than 72 million people rely on Medicaid. In fact, 1 in 10 adults with a history of cancer utilize Medicaid for insurance coverage. Millions of others rely on plans offered through the ACA Marketplaces.
This health coverage is essential to ensuring timely access to breast cancer screening, diagnosis and treatment — care that might otherwise be delayed until the disease is more advanced and expensive to treat. The National Breast and Cervical Cancer Early Detection Program, a state-federal partnership which aims to increase early detection among women with low-incomes, works in conjunction with state Medicaid programs to provide treatment for those who are diagnosed with breast cancer — an effort that maximizes our nation's investment in both programs.
The bill requires work reporting requirements that would restrict access to quality and affordable healthcare for millions of patients. Even if breast cancer patients qualify for exceptions from the work reporting requirements, which remains unclear, they would still be required to navigate through administrative red tape to demonstrate their qualification. Additionally, this legislation proposes eligibility checks on Medicaid enrollees every 6 months, further increasing the administrative burden for enrollees, which is the last thing a person undergoing cancer treatment should have to face.
Additional policies included in the bill make several changes to ACA Marketplace plans, including codifying harmful regulations, shortening the open enrollment period, and enhancing eligibility checks, eroding coverage for the millions of Americans, including breast cancer patients and survivors.
Komen urges Congress to do better for the breast cancer community and asks the Senate to reject the policies which will hurt the breast cancer patients, survivors and many other Americans when they consider the budget reconciliation bill next. Join us in this effort by contacting your U.S. Senators here.
About Susan G. Komen®
Susan G. Komen® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250522000927/en/
Contacts
press@komen.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
11 minutes ago
- CBS News
Blue state governors to testify on "sanctuary policies" amid L.A. protests over immigration raids
Washington — Three Democratic governors are defending their responses to the migrant crisis and dispute claims of failing to cooperate with federal authorities, according to prepared remarks that will be delivered Thursday before a House oversight panel. New York Gov. Kathy Hochul, Illinois Gov. J.B. Pritzker and Minnesota Gov. Tim Walz are among the witnesses scheduled to testify before the House Oversight and Government Reform Committee on so-called "sanctuary policies". "Let me be clear: Sanctuary policies don't protect Americans. They protect criminal illegal aliens," Oversight Chair James Comer, a Kentucky Republican will say in his opening statement. The governors' appearances come as President Trump and California Governor Gavin Newsom remain embroiled in a legal and political standoff over the deployment of the National Guard troops and Marines to quell immigration protests in Los Angeles. Demonstrations have spread to other U.S. cities, including New York and Chicago following a series of deportation raids. "Minnesota is not a sanctuary state," Walz will tell lawmakers. "It is ridiculous to suggest that Minnesota — a state that is over 1,500 miles away from the Southern border and a thousand miles from lawmakers in Washington, D.C. who decide and implement border policy is somehow responsible for a failure of immigration enforcement." The former vice presidential candidate has drawn intense scrutiny not only over immigration policy but also for his handling of social justice protests that broke out in Minneapolis following the death of George Floyd in 2020. Trump administration officials have cited Walz' actions to justify the president's decision to federalize troops in California. While Walz does not appear to directly address the controversy in his testimony, he says he is "disappointed" in the federal government's overall approach. "As governor of Minnesota, it is incumbent on me to use the state's resources to help Minnesota families—not turn those resources over to the administration so they can stage another photo-op in tactical gear or accidentally deport more children without observing due process," Walz is set to say. Ahead of the hearing, the GOP-led panel released a video compilation of various news clips accusing the governors of "shielding" undocumented immigrants and "causing chaos" in their states. A memo from Hochul's office suggested the hearing could be "derailed by wild accusations" and "twisted characterizations" but noted the governor's position is "clear" when it comes to supporting strong borders and comprehensive immigration reform. "New York state cooperates with U.S. Immigration and Customs Enforcement (ICE) in criminal cases," Hochul says. "And our values as New Yorkers demand that we treat those who arrive here in search of a better life with dignity and reject policies that tear law-abiding families apart." Hochul also addresses the influx of more than 220,000 migrants to New York City since early 2022, many of whom were bussed from border states, calling it "an unprecedented humanitarian crisis." "We have responded to this crisis with both compassion and pragmatism," Hochul states."And as a result, we largely prevented what could have become an additional crisis — one of street homelessness and tent cities." Pritzker says Illinois also stepped up to the challenge, and blamed the lack of federal intervention and cooperation from border states for exacerbating the problem. "As governor, my responsibility is to ensure that all Illinoisans feel safe in their homes, their businesses, and their communities," Pritzker is prepared to say. "That is why my administration continued to make significant investments in public safety, even as our resources were strained because of the lack of federal support during the crisis — expanding our state police force and investing in efforts to reduce gun violence." Thursday's session follows a March hearing on sanctuary cities with four Democratic mayors: Eric Adams, of New York, Mike Johnston of Denver, Brandon Johnson of Chicago and Michelle Wu of Boston. Comer launched an investigation in January into "sanctuary jurisdictions", including states, counties or cities, to examine their impact on public safety and federal immigration enforcement. President Trump has vowed to crack down on localities that don't back his immigration agenda. Earlier this month, the Department of Homeland Security removed its list of sanctuary jurisdictions after several cities challenged the findings.
Yahoo
15 minutes ago
- Yahoo
The $11 trillion gap between White House and economists on Trump's 'big, beautiful' bill
An array of economists — from the Congressional Budget Office to the Tax Foundation to the Penn-Wharton Budget Model — have reached a similar conclusion: Trump's signature legislation comes with a price tag in the neighborhood of $3 trillion over the next decade. They're all wrong, the White House says. And not just by a little. President Trump and his aides have instead offered claims that the bill will make money and that the final tally for both the tax-cutting legislation and other parts of the Trump agenda will usher in a new golden age not just for the US economy but also for government debt. The claims from 1600 Pennsylvania Avenue go as high as $8 trillion in black ink (an $11 trillion chasm with the experts) in claims that go beyond what even Capitol Hill Republicans are projecting. As for reconciling the two, some economists essentially throw up their hands. "You can't square it because it's ridiculous," Erica York of the Tax Foundation said. "The bill unambiguously will increase deficits, it will not contribute that much to economic growth," she added, noting that the bill is largely focused on extending current tax rates that would not be expected to push the economy significantly upward from current levels. Yet the White House has remained steadfast even as this gap has led to increased tensions as the bill goes through another round of adjustments on Capitol Hill. A Wednesday appearance before Congress by Treasury Secretary Scott Bessent was marked by lawmakers — mostly Democratic, but some Republicans as well — raising the debt issue. In one colorful moment, Democratic Rep. Mike Thompson of California asked Bessent to point to an independent expert "not on the payroll of this administration" who says this bill will not add to our debt. Bessent then cited Arthur Laffer, the former Reagan official and longtime Trump supporter who received the Presidential Medal of Freedom during the president's first term. The comment led to laughter in the chamber, with Thompson shooting back, "I don't think that one counts." It was a hearing where Bessent declined to repeat some of the administration's most aggressive claims, saying instead that "it remains to be seen" whether the bill will add to the national debt. Others have not been so restrained about the impact of Trump's overall agenda. "We're going to cut the deficit by $8 trillion over the next 10 years," press secretary Karoline Leavitt offered recently on Fox News. And a recent White House memo offered a slightly lower figure of about $6.7 trillion to $6.9 trillion in deficit reductions over the coming decade. One issue is that White House projections rely on a set of assumptions that are often internally contradictory, such as taking credit for taxes spurring economic growth while simultaneously saying they have no cost. Other parts of the bill would enact temporary tax cuts — and then take credit for lower costs there — while also claiming other permanent cuts are free. That's in addition to an overriding assumption at the White House that, essentially, things break historically right for the US economy and sustained 3% economic growth is in the offing. That's above even what House Republicans are projecting, as lawmakers there have rallied behind a lower (but still very aggressive) assumption of 2.6% growth. Both projections are unlikely, Marc Goldwein of the Committee for a Responsible Federal Budget said. "Some people are at 2%, some people are at 1.6% ... that is the neighborhood," he said of a series of projections for growth that hover around 1.8%. He added in an interview that even if sustained 3% growth were to happen, "it would have very little to do with this tax bill." Yet the White House has repeatedly dismissed the experts. Trump budget chief Russ Vought recently told reporters that everything "is part of a coherent fiscal agenda" and that the combination of tax cuts, tariffs, additional promised spending cuts, and "reforms we can do ourselves" to programs like Medicaid will lead to good outcomes for the US bottom line. White House projections also fully embrace recent CBO projections of $2.8 trillion in tariff revenues over the coming decade. But that embrace appears to ignore a prediction in the same report that tariffs will "reduce the size of the U.S. economy" and also lead to a potential inflation increase of 0.4 percentage points in 2025 and 2026. York has calculated that even two seemingly minor adjustments — taking the slightly lower but still very aggressive House estimate of 2.6% economic growth and factoring in the economic costs of tariffs — means the bill "is basically a wash or even negative for GDP." "They're picking and choosing," she added. Read more: What Trump's tariffs mean for the economy and your wallet And few are expecting tariffs to stay steady in the coming months, not to mention the coming years. Tariff levels are under active negotiation — two fronts this week are duties on goods from China and India — as the CBO report assumed rates remain steady not just during Trump's term, but also years after he is scheduled to leave office. The tariffs are also under a considerable cloud of legal uncertainty, with an appeals court ruling on Tuesday that Trump's "Liberation Day" tariffs could stay in force for now while it considers whether they are legal. "Even if they are upheld by the courts, it still seems like the Trump administration is willing to negotiate them down somewhat," York noted, "and then what happens in four years when a new administration comes in?" Ben Werschkul is Washington correspondent for Yahoo Finance. David Foster is a graphic artist for Yahoo Finance. Click here for political news related to business and money policies that will shape tomorrow's stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
20 minutes ago
- Business Wire
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), regardless of prior dengue exposure. Recruitment for the trial has begun, and the first participants are now enrolling in Singapore. 'Approximately half of the world's population live in areas with a risk for dengue, making it a serious public health threat,' said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines, global clinical development, Merck Research Laboratories. 'The initiation of the MOBILIZE-1 study, the first Phase 3 trial in our clinical development program, marks a key milestone in our work to help address this widespread mosquito-borne disease. If successful, V181 could provide an important single-dose option for at risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe.' Merck is committed to research and innovation that aims to help protect the millions of people at risk for dengue virus infection and is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is a significant health threat. About MOBILIZE-1 (NCT07013487) MOBILIZE-1, also known as V181-005, is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety, immunogenicity and efficacy of V181, an investigational vaccine for the prevention of dengue disease. The study aims to enroll approximately 12,000 healthy individuals 2 to 17 years of age who will be randomized to receive either a single dose of V181 or placebo. The study is planned to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific region, including Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam. The primary endpoints of the study are safety and efficacy of a single dose of V181 in preventing symptomatic virologically confirmed dengue (VCD) of any severity, due to any of the four dengue serotypes, regardless of prior dengue exposure. The key secondary efficacy endpoint is evaluating a single dose of V181 in preventing symptomatic VCD of any severity due to each of the four dengue serotypes, regardless of prior dengue exposure. Additional secondary endpoints include evaluating a single dose of V181 in preventing symptomatic VCD with warning signs, severe VCD and hospitalization. For more information on the trial, visit About V181 V181 is a live attenuated quadrivalent vaccine currently being investigated for the prevention of dengue disease caused by any of the four dengue virus types (DENV-1, DENV-2, DENV-3, and DENV-4). V181 is designed to be a single-dose vaccination and is being studied in individuals to provide protection against dengue, including severe forms, whether the individuals have been previously infected with the dengue virus or had no prior infections. About Dengue disease Dengue disease is one of the fastest growing mosquito-borne diseases that affects not just the health but often the economic stability of communities across the globe. It is a rapidly emerging cause of serious and sometimes debilitating illness in tropical and subtropical countries. With approximately half of the world's population, or four billion people, at risk for dengue disease, it represents a critical public health challenge. Globally, around 105 million dengue viral infections occur annually, with approximately 50-60 million being symptomatic on average per year. While the majority of infections are uncomplicated, serious illness caused by dengue can be severe and lead to death (on average, ~4-11 million cases result in hospitalizations per year and there is an average annual incidence of ~29,000 dengue-related deaths worldwide). Symptoms of mild dengue fever may include a high fever, a rash and muscle and joint pain. Dengue fever might evolve to severe dengue, formerly known as dengue hemorrhagic fever, which can cause severe bleeding, a sudden drop in blood pressure, and in rare cases, death. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
